Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How You Will Achieve More:

The Head of Medical Affairs, reporting to the EVP, Chief Medical Officer, will be accountable for building and leading a high-functioning and integrated Medical Affairs team. The successful candidate will partner closely with Program Team Leads, R&D and Commercial, responsible for medical affairs strategy and plan for Intellia’s growing portfolio of products and pipeline. This leadership position requires a highly motivated individual with experience in evidence generation, scientific communication, stakeholder engagement, and extensive experience in successful product launches. The Head of Medical Affairs will be responsible for continuing to build and ready medical capabilities and preparing the organization to support US commercialization activities and global Phase 3 Clinical Trials while establishing scientific credibility and medical trust with key stakeholders. The head is a contributing member of the Development Leadership Team and the MAC.

Responsibilities:

Build and lead a highly engaged and effective Medical Affairs team, driving medical affairs activities across global and regions, and serving as a player-coach as required
The Head of Medical Affairs will continue to build, mentor, and manage medical affairs capabilities across key functional areas including Medical Strategy, Field Medical, Medical Information, Scientific Communication, Patient Advocacy, and Medical Operations.
Serve as a strategic partner to internal stakeholders from Program Teams, R&D to Commercial
Lead a cross-functional team to develop an integrated evidence generation strategy and ensure timely execution of Medical Affairs led studies, including post-approval observational studies, disease registries, and patient surveys
Lead cross-functional review & approval of investigator-initiated studies as well as local and/or regional medical affairs study proposals
Partner with R&D stakeholders to ensure medical input on development activities, such as input on patient reported outcome measures in registrational studies and timely communication of clinical data
Partner with Clinical Operations team to support company sponsored studies, including site selection, study initiation, trial enrollment, and in select cases, study closing
Collaborate with R&D and Commercial stakeholders to develop and implement an integrated stakeholder engagement strategy and plan; oversee engagement activities of stakeholders across global and regions
Lead cross-functional efforts to ensure strong medical and scientific presence at key congresses, delivering an effective scientific share of voice
Collaborate with stakeholders to develop and implement responsible early access strategy and plans
Partner closely with local and regional stakeholders to support payer engagement and patient access
Evaluate medical insights, stakeholder needs and evolving scientific information to inform business and portfolio priorities.
Guide medical communication activities, external scientific engagement, educational initiatives, and publication-related planning.

Supervisory Responsibilities

Recruits, interviews, hires, and trains leading roles for Medical Affairs functions.
Managed the functional leaders of the Medical Affairs organization.
Provides constructive and timely performance evaluations to my direct reports.
Invests in the development of Medical Affairs employees.
Handles discipline and termination of employees as needed.
Reviews, develops, and implements actions to improve opportunities identified in annual Engagement Survey.

About You:

Excellent written and verbal communication and interpersonal skills
Demonstrated reputation as a well-respected, dynamic team leader with effective people management skills and a proven track record of successful product launches
Demonstrated track record to bring strategic insight in development and execution of medical and/or scientific plans in support of product development and differentiation, addressing healthcare stakeholder requirements, and clinical practice patterns on the national and global level.
Demonstrated ability to understand current and evolving environmental and market access issues and capable of managing shifting priorities in a rapidly changing environment
Ability to think strategically, critically analyze and synthesize complicated data and scientific information
Excellent and demonstrated interpersonal skills; ability to understand and respond to competing priorities, manage and handle conflict constructively.
MD or PhD in relevant education
15+ years of medical affairs leadership experience, including hands-on experience in evidence generation, stakeholder engagement, including payer engagement, is required
Prior experience in gene therapy, gene editing, rare diseases, or expertise in cardiology preferred but not required
Strong understanding of clinical trial design and global healthcare delivery systems.
Strong knowledge and application of ICH GCP, GxP, global regulations and good document management practices.
Located in the greater Boston area highly preferred
Ability to travel domestically and internationally (~20%)

#LI-Hybrid

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Applications are accepted on a rolling basis, and will continue to be accepted until the position is filled at which point the position will be taken down.

The base salary for this position is expected to range between $389,590.00 - $476,166.00 USD per year.

The salary offered is determined based on a range of factors including, but not limited to, relevant education and training, overall related experience, specialized, rare or in-demand skill sets, internal comparators and other business needs. Upon joining Intellia, your salary will be reviewed periodically and additional factors such as time in role and performance will be considered. Intellia may change the published salary range based on company and market factors.

Additional compensation includes a performance-based annual cash bonus, a new hire equity grant, and eligibility to be considered for annual equity awards the value of which are determined annually at the Company’s discretion.

For more information about Intellia’s benefits, please click here.

About the company

Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Get referred to Intellia Therapeutics

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA priority review for lonvo-z validates Intellia's regulatory path and commercial narrative.
June 13, 2026 HAELO data showed strong attack reduction and NEJM publication.
Citizens JMP set $30 target on September 9, 2026, citing lonvo-z upside.

What critics are saying

March 10, 2027 PDUFA approval failure would crush lonvo-z commercialization and financing.
The $400 million OrbiMed facility secures assets and raises debt-servicing pressure.
Revenue fell to $7.66 million on August 6, 2026, leaving Intellia clinical-dependent.

What makes Intellia Therapeutics unique

Lonvo-z became the first in vivo CRISPR BLA accepted, September 8, 2026.
Intellia owns broad CRISPR-Cas9 IP and delivery expertise from Cambridge, Massachusetts.
One-time editing and ex vivo programs create platform optionality beyond hereditary angioedema.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays

Growth & Insights and Company News

6 month growth

1 year growth

-1%

2 year growth

MarketScreener

Oct 13th, 2026

Intellia Therapeutics, Inc. announces appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026.

Intellia Therapeutics, Inc. announces appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Published on 10/13/2026 at 10:21 am EDT S&P Capital IQ Intellia Therapeutics, Inc. announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company?s translational, development, regulatory and medical affairs functions. Dr. Marantz?s leadership experience spans research and development, medical affairs, business development and portfolio strategy across multiple specialties and rare diseases. Most recently, she served as Chief Medical Officer for Scholar Rock, where she led the development organization in advancing multiple clinical programs across neuromuscular, oncology and obesity, culminating in the U.S. approval of ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy. During her tenure at Scholar Rock, Dr. Marantz led simultaneous regulatory submissions to the U.S. Food and Drug Administration and European Medicines Agency followed by successful engagement with Japan?s Pharmaceuticals and Medical Devices Agency, achieving alignment for a Japanese New Drug Application submission without clinical trial data in Japanese patients. Prior to her role at Scholar Rock, Dr. Marantz held senior leadership positions at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD and Millennium Pharmaceuticals, playing key roles in the development and commercialization of over a dozen products across hematology/oncology, neurology and rare diseases. She is a member of the Board of Directors for Arcturus Therapeutics, Inc. Dr. Marantz received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from the Medical University of South Carolina, and an MBA from the University of California at Berkeley. (C) S&P Capital IQ - 2026

Associated Press

Oct 13th, 2026

Intellia appoints Scholar Rock's Jing Marantz as chief medical officer ahead of gene editing launch

Intellia Therapeutics has appointed Jing L. Marantz as executive vice president and chief medical officer, effective October 26, 2026. She will lead the company's translational, development, regulatory, and medical affairs functions. Marantz has more than 25 years of experience in biopharmaceuticals. She was most recently chief medical officer at Scholar Rock, where she oversaw the US approval of ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy. She also held senior roles at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals. Chief executive officer John Leonard said her experience will be critical as Intellia seeks to commercialise its first potential in vivo gene editing product and advances Phase 3 trials in transthyretin amyloidosis.

TrendPulse

Sep 18th, 2026

CRISPR Therapeutics outlook: scaling gene editing by 2036.

CRISPR Therapeutics outlook: scaling gene editing by 2036. Key takeaways. * CRISPR Therapeutics currently reports $10.2 million in quarterly revenue against a $91.2 million net loss, highlighting the heavy R&D burden of its current pipeline. * The company is pivoting from ex-vivo therapies like Casgevy toward in-vivo editing, which could expand its addressable patient population from 150,000 to 400,000. * By 2036, the success of SyNTase editing and in-vivo delivery methods will determine if the firm transitions from a niche biotech to a diversified genomic medicine powerhouse. TrendPulse analysis. Industry context. The gene-editing landscape is moving beyond the "proof of concept" phase into a period of rigorous commercial validation. Historically, the sector has been defined by high-cost, one-time curative treatments. However, the industry is now facing a "delivery bottleneck." Competitors like **Intellia Therapeutics** and **Beam Therapeutics** are also racing to solve the in-vivo delivery challenge, as the market increasingly favors standardized, off-the-shelf products over the bespoke, patient-specific manufacturing processes that currently dominate the space. Furthermore, the regulatory environment is becoming more sophisticated. As seen with recent setbacks at major pharmaceutical firms like **Novartis**, regulators are no longer satisfied with biomarker improvements alone. They now demand clear, long-term clinical outcomes that translate into tangible patient health benefits. This shift forces companies like CRISPR Therapeutics to prove not just that they can edit a gene, but that the edit reliably prevents disease progression in real-world settings. The industry is effectively moving from a "technology-first" mindset to a "clinical-outcome-first" mandate. Why this matters. For investors and industry stakeholders, the next decade represents a transition from speculative growth to operational maturity. The primary risk is no longer just scientific failure, but commercial viability. If CRISPR Therapeutics successfully transitions to in-vivo delivery, it will fundamentally change the economics of the business, moving from a high-cost service model to a scalable product model. This would likely trigger a wave of M&A activity, as large-cap pharmaceutical companies look to acquire proven, scalable genomic platforms to replenish their aging pipelines. However, the path to 2036 is fraught with "clinical disconnect" risks - where the editing works, but the patient outcome does not improve as expected. Decision-makers should monitor the company's ability to manage its cash burn while navigating these long-term trials. The winners in this space will be those who can balance the high costs of R&D with a clear, cost-effective path to commercialization. Investors should look for evidence of manufacturing efficiency and partnerships that can handle the global distribution of these complex therapies once they reach the market. The bottom line. CRISPR Therapeutics' long-term value hinges on its ability to transition from complex, ex-vivo procedures to scalable in-vivo therapies that deliver measurable, long-term clinical outcomes. Read the full article. This analysis is based on reporting from nasdaq Finance AI-powered news analysis · September 18, 2026 Editorially Reviewed

MarketBeat

Sep 9th, 2026

Intellia Therapeutics' (NTLA) market outperform rating reiterated at Citizens Jmp.

Intellia Therapeutics' (NTLA) market outperform rating reiterated at Citizens Jmp. September 9, 2026 Key points. * Citizens JMP reiterated its "Market Outperform" rating on Intellia Therapeutics and maintained a $30 price target, implying approximately 135% upside from the reported $12.74 share price. * Analyst sentiment remains mixed: Intellia has an average rating of "Hold" and an average price target of $20.98, despite recent "Outperform" and "Buy" upgrades or reiterations from several firms. * Intellia reported a quarterly loss of $0.80 per share, in line with estimates, but revenue of $7.66 million fell short of the $12.98 million consensus and declined 46.4% year over year. * MarketBeat previews top five stocks to own in October. Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "market outperform" rating reissued by investment analysts at Citizens Jmp in a report issued on Wednesday, Benzinga reports. They presently have a $30.00 price objective on the stock. Citizens Jmp's price target points to a potential upside of 135.48% from the stock's current price. NTLA has been the topic of several other research reports. Evercore raised Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 price objective on the stock in a research note on Friday, August 7th. HC Wainwright restated a "buy" rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday. Sanford C. Bernstein increased their target price on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Wedbush lifted their price objective on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Wednesday. Finally, Citigroup restated a "market outperform" rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $20.98. Intellia Therapeutics stock performance. NASDAQ:NTLA opened at $12.74 on Wednesday. The stock has a fifty day simple moving average of $12.78 and a 200-day simple moving average of $13.42. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -3.79 and a beta of 1.82. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $28.25. Discover more Get Business Reports Cryptocurrency market data Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.80). The company had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The firm's revenue for the quarter was down 46.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.98) EPS. As a group, equities research analysts predict that Intellia Therapeutics will post -3.21 EPS for the current fiscal year. Insider activity. In other news, EVP Edward J. Dulac III sold 4,677 shares of the company's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the sale, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the firm's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is currently owned by insiders. Hedge funds weigh in on Intellia Therapeutics. Several hedge funds and other institutional investors have recently made changes to their positions in NTLA. BlackRock Inc. acquired a new stake in Intellia Therapeutics during the 2nd quarter worth $260,721,000. ARK Investment Management LLC lifted its holdings in Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company's stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company's stock worth $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp raised its position in Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company's stock valued at $57,705,000 after purchasing an additional 1,447,967 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company's stock worth $24,243,000 after purchasing an additional 107,333 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock. Intellia Therapeutics news roundup. Here are the key news stories impacting Intellia Therapeutics this week: * The FDA granted Priority Review to Intellia's biologics license application for lonvo-z and set a PDUFA decision date of March 10, 2027. If approved, lonvo-z could become the first in vivo CRISPR-based therapy and the only one-time treatment for HAE, offering substantial commercial differentiation. * HC Wainwright reaffirmed its Buy rating and assigned a $25 price target, implying substantial potential upside from the stock's recent $12.74 level. The target reflects optimism about lonvo-z and Intellia's CRISPR platform. * Wedbush raised its price target to $13 from $12 but maintained a Neutral rating. The revised target indicates only limited near-term valuation upside and shows that analysts remain cautious despite the FDA milestone. * Intellia was highlighted among genomics companies attracting investor interest in 2026, reinforcing broader enthusiasm for gene-editing and precision-medicine technologies, but the article did not announce a new company-specific development. About Intellia Therapeutics. Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical-stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease-causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders. Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Intellia Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list. While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Continue following MarketBeat

MarketScreener

Sep 4th, 2026

Intellia Therapeutics, Inc. secures non-dilutive debt facility with OrbiMed for up to $400 million.

Intellia Therapeutics, Inc. secures non-dilutive debt facility with OrbiMed for up to $400 million. Published on 09/04/2026 at 12:06 pm EDT S&P Capital IQ Intellia Therapeutics, Inc. announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The facility includes an initial term loan of $75 million that was funded at closing; 5 additional tranches totaling up to $225 million that can be drawn at Intellia?s option subject to its achievement of specified milestones related primarily to lonvo-z; and an additional $100 million available subject to mutual agreement between the parties during the five-year term of the agreement. Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K. TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed. (C) S&P Capital IQ - 2026

Intellia Therapeutics

Head of Medical Affairs

About the job

About the company

Get referred to Intellia Therapeutics

Simplify's Take

What believers are saying

What critics are saying

What makes Intellia Therapeutics unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth